Regeneron’s antibody therapy, REGEN-COV, is currently authorized in the U.S.
Regeneron’s antibody drug cuts COVID-19 risk by nearly 82% for up to 8 months
© The Crystal Eyes
Regeneron’s antibody therapy, REGEN-COV, is currently authorized in the U.S.
© The Crystal Eyes